Iressa 250 mg Tablet

Product Description

Iressa 250 mg tablet is an innovative treatment specifically designed for adults diagnosed with non-small cell lung cancer (NSCLC) that has metastasized to other regions of the body, particularly in patients exhibiting mutations in the EGFR gene and who have not previously undergone cancer therapy. This targeted therapy works by inhibiting the activity of the abnormal EGFR protein, which plays a crucial role in the growth and spread of cancer cells, thus helping to slow down disease progression and improve survival outcomes. It's important to note that Iressa is not recommended for use in pediatric patients due to insufficient data regarding its safety and efficacy in children and adolescents. Patients should be aware of potential side effects, which may include skin rashes, diarrhea, and liver function abnormalities, necessitating regular monitoring by healthcare professionals. Before starting treatment with Iressa, discussing any existing medical conditions and medications with a healthcare provider is essential to avoid harmful interactions. By providing a tailored approach to NSCLC management, Iressa 250 mg helps enhance treatment options for eligible patients, making it a vital component in the oncology landscape. Always consult your doctor for personalized advice and to ensure this medication aligns with your overall treatment plan.